Areas of Expertise
Scientists and physicians of the Parker Hughes Institute and Parker Hughes Cancer Center have significant expertise in the development of new agents and new treatment strategies for the treatment of cancer.
The Institute is most noted for its development of several new agents for the treatment of leukemias. These agents have shown effectiveness in the treatment of childhood and adult leukemias and lymphomas.
New agents are currently in clinical trials for the following:
Acute Lymphocytic Leukemia
Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Plasma Cell Leukemia
Hairy Cell Leukemia
In addition to the state-of-the-art treatment strategies currently offered, new agents are under development for the following: